This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
AbbVie (ABBV) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
AbbVie (ABBV) delivered earnings and revenue surprises of 3.11% and 2.96%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Merck (MRK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Merck (MRK) closed at $125.92 in the latest trading session, marking a +1.24% move from the prior day.
What Lies in Store for Healthcare ETFs in Q2 Earnings?
by Sweta Killa
The healthcare sector has gained momentum lately on market rotation, with investors rushing to buy beaten-down stocks while shunning the hot technology sector.
Should You Buy, Sell or Hold Merck (MRK) Ahead of Q2 Earnings?
by Kinjel Shah
Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports second-quarter 2024 earnings.
Merck (MRK) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Merck (MRK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Merck (MRK) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
Merck (MRK) closed at $125.69 in the latest trading session, marking a -0.06% move from the prior day.
Elanco (ELAN) Stock Declines After Sale of Aqua Business
by Zacks Equity Research
Elanco (ELAN) completes the sale of Aqua Business to Merck Animal Health for $1.3 billion to strengthen its financial flexibility and accelerate debt reduction.
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Zacks Industry Outlook Eli Lilly, Novo Nordisk, Merck and Pfizer
by Zacks Equity Research
Eli Lilly, Novo Nordisk, Merck and Pfizer have been highlighted in this Industry Outlook article.
Merck (MRK) Up 17% YTD on Keytruda Strength: Should You Buy?
by Kinjel Shah
Merck (MRK) stock is being driven by the strong sales of key products like Keytruda and Gardasil and positive pipeline and regulatory developments.
Moderna (MRNA) Stock Rises 22% YTD: Time to Buy the Stock?
by Sundeep Ganoria
Shares of Moderna (MRNA) continue to soar thanks to the encouraging development of its non-COVID pipeline. The company's potential product launches over the next few years make it worth looking at.
Is MannKind (MNKD) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how MannKind (MNKD) and Merck (MRK) have performed compared to their sector so far this year.
4 Large Drug Stocks to Watch as Innovation, M&A Pick Up
by Kinjel Shah
Drug and biotech companies are seeing significant innovation in 2024. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and Pfizer (PFE) are worth retaining in one's portfolio.
Merck (MRK) Stock Moves 0.28%: What You Should Know
by Zacks Equity Research
In the closing of the recent trading day, Merck (MRK) stood at $128.12, denoting a +0.28% change from the preceding trading day.
Immutep (IMMP) Up as Combo Therapy Meets Carcinoma Study Goals
by Zacks Equity Research
Immutep (IMMP) jumps 15% on positive results from a late-stage study evaluating its candidate, efti, in combination with Keytruda to treat first-line head and neck squamous cell carcinoma patients.
The Zacks Analyst Blog Highlights Exxon Mobil, Merck & Co, Qualcomm and Armanino Foods of Distinction
by Zacks Equity Research
are included in this Analyst Blog Exxon Mobil, Merck & Co, Qualcomm and Armanino Foods of Distinction
Top Research Reports for Exxon Mobil, Merck & Qualcomm
by Santanu Roy
Today's Research Daily features new research reports on 16 major stocks, including Exxon Mobil Corporation (XOM), Merck & Co., Inc. (MRK) and QUALCOMM Incorporated (QCOM), as well as two micro-cap stocks Armanino Foods of Distinction, Inc. (AMNF) and AMCON Distributing Company (DIT).
Merck (MRK) Beats Stock Market Upswing: What Investors Need to Know
by Zacks Equity Research
Merck (MRK) reachead $126.04 at the closing of the latest trading day, reflecting a +0.21% change compared to its last close.
Eli Lilly (LLY) to Buy Morphic for $3.2B, Boost IBD Presence
by Zacks Equity Research
Eli Lilly's (LLY) acquisition of Morphic (MORF) is set to expand its immunology pipeline by adding the latter's lead candidate, MORF-057, which is being developed for IBD conditions.
The Zacks Analyst Blog Highlights Eli Lilly, Sanofi Merck, AstraZeneca's and Roche
by Zacks Equity Research
Eli Lilly, Sanofi Merck, AstraZeneca's and Roche are included in this Analyst Blog.
Pharma Stock Roundup: FDA Nod to LLY's Kisunla, SNY's Dupixent Gets EU Nod for COPD
by Kinjel Shah
Eli Lilly (LLY) wins FDA approval for its Alzheimer's disease drug, Kisunla. (donanemab). Sanofi (SNY) and Regeneron's Dupixent gets approval for COPD in Europe.
Roche's (RHHBY) Combo Therapy Misses Lung Cancer Study Goals
by Zacks Equity Research
Roche (RHHBY) announces that its mid to late-stage lung cancer study evaluating the tiragolumab combination therapy compared with Keytruda fails to meet primary endpoints.
AstraZeneca (AZN) Imfinzi Combo Gets CHMP Nod for Expanded Use
by Zacks Equity Research
The CHMP recommends approval of AstraZeneca's (AZN) Imfinzi plus Lynparza for treating primary advanced or recurrent endometrial cancer based on data from the phase III DUO-E study.